Table 2.

Clinical studies.

Authors	Year	Study Design	Study Population	Adm	Dosage	Schedule of Treatment	Follow-up	Outcomes
Pecori Giraldi et al. [69]	1989	cohort	Open Angle Glaucoma (OAG)	IM	1 g/day	10 days	3 months	Reduction in the scotomatous area (computerized central perimetry) and decrease in mean defect (automated perimetry)
Parisi V et al. [71]	1999	case-control	OAG −3 dB > Mean Deviation (MD) < −6 dB	IM	1 g/day	60 days 120 days of washout (2 cycles)	360 days	Visual Evoked Potential (VEP) and Pattern Electroretinogram (PERG) parameters
Virno M et al. [70]	2000	case-control	OAG	IM	1 g/day	15 days 180 days of washout (20 cycles)	10 years	Visual field worsening (increase of non-perception area >500 mm2)
Rejdak et al. [73]	2003	cohort	OAG	Oral	1 g/day	14 days 2 days of washout (2 cycles)	56 days	VEP parameters
Parisi V [72]	2005	case-control	OAG −3 dB > MD < −6 dB	IM	1 g/day	60 days 120 days of washout (14 cycles)	8 years	VEP and PERG parameters
Parisi V et al. [74]	2008	case-control	OAG −2 dB > MD < −14 dB	IM Oral	1 g/day 1600 mg/day	60 days 120 days of washout (2 cycles)	360 days	VEP and PERG parameters
Ottobelli L et al. [75]	2013	retrospective cohort	progressing OAG	Oral (solution)	500 mg/day	120 days 60 days of washout (4 cycles)	2 years	Rate of visual field progression
Roberti et al. [78]	2014	experimental and clinical (case-control)	OAG −3 dB > MD < −12 dB	Topic (eye drops)	3 drops/day	60 days	90 days	VEP and PERG parameters
Parisi V et al. [79]	2015	case-control	OAG MD > −10 dB	Topic (eye drops)	3 drops/day	120 days 60 days of washout	180 days	VEP and PERG parameters

Summary of clinical studies evaluating the effect of citicoline in glaucoma patients by means of visual field and electrophysiological parameters. Adm = administration. IM = intramuscular.